Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer

Gudenkauf, LM; Chavez, MN; Maconi, ML; Geiss, C; Seyedroudbari, A; Thin, P; Hoogland, AI; Nguyen, K; Murthy, V; Armstrong, WR; Komrokji, K; Oswald, LB; Jim, HSL; El-Haddad, G; Fendler, WP; Herrmann, K; Cella, D; Czernin, J; Hofman, MS; Dicker, AP; Calais, J; Tagawa, ST; Gonzalez, BD

Author(s): Gudenkauf, LM; Chavez, MN; Maconi, ML; Geiss, C; Seyedroudbari, A; Thin, P; Hoogland, AI; Nguyen, K; Murthy, V; Armstrong, WR; Komrokji, K; Oswald, LB; Jim, HSL; El-Haddad, G; Fendler, WP; Herrmann, K; Cella, D; Czernin, J; Hofman, MS; Dicker, AP; Calais, J; Tagawa, ST; Gonzalez, BD;
Details: Publication Year 2023-06,Volume 64,Issue #6,Page 869-872
Journal Title: Journal of Nuclear Medicine
Publication Type: Research article
Abstract: The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first (177)Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.
Publisher: Society of Nuclear Medicine and Molecular Imaging
Keywords: Male; Humans; *Prostatic Neoplasms/radiotherapy/drug therapy; Radioisotopes/therapeutic use; Patient Reported Outcome Measures; genitourinary oncology; patient-reported outcomes; prostate cancer; radionuclide therapy; radiopharmaceuticals
Department(s): Cancer Imaging
PubMed ID: 36635088
Publisher's Version: https://doi.org/10.2967/jnumed.122.264946
Open Access at Publisher's Site: https://doi.org/10.2967/jnumed.122.264946
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-09-05 07:38:03

Last Modified: 2023-09-05 07:38:18